Canaccord Genuity Maintains Buy on DexCom, Lowers Price Target to $99

Benzinga · 10/31/2025 20:30
Canaccord Genuity analyst William Plovanic maintains DexCom (NASDAQ:DXCM) with a Buy and lowers the price target from $106 to $99.